Arsenic trioxide Accord

RSS

arsenic trioxide

Authorised
This medicine is authorised for use in the European Union.

Overview

Arsenic trioxide Accord is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic ‘translocation’ (when there is a swap of genes between two chromosomes). The translocation affects the way the white blood cells grow, and as a result they lack the ability to use retinoic acid (vitamin A). Patients with APL are normally treated with retinoids (substances derived from vitamin A).

Arsenic trioxide Accord is used in:

  • Patients with newly diagnosed low or intermediate risk APL where it is used together with the medicine all-trans-retinoic acid.
  • Patients with APL whose disease has not responded to previous treatment with a retinoid and cancer medicines, or when their disease has come back after this type of treatment.

Arsenic trioxide Accord contains the active substance arsenic trioxide and is a ‘generic medicine’. This means that Arsenic trioxide Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Trisenox.

This EPAR was last updated on 26/11/2019

Authorisation details

Product details
Name
Arsenic trioxide Accord
Agency product number
EMEA/H/C/005175
Active substance
Arsenic trioxide
International non-proprietary name (INN) or common name
arsenic trioxide
Therapeutic area (MeSH)
Leukemia, Promyelocytic, Acute
Anatomical therapeutic chemical (ATC) code
L01XX27
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Accord Healthcare S.L.U.
Date of issue of marketing authorisation valid throughout the European Union
14/11/2019
Contact address

World Trade Center
Moll de Barcelona
s/n, Edifici Est 6ª planta
08039 Barcelona
Spain

Product information

14/11/2019 Arsenic trioxide Accord - EMEA/H/C/005175 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:

  • Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/μl) in combination with all-trans-retinoic acid (ATRA)
  • Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.
    The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Assessment history

How useful was this page?

Add your rating